Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsSunpharmaceuticalindustries

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Buy Sun Pharma, see higher levels: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Sun Pharmaceutical Industries as the stock may head higher.

    • Buy Sun Pharma for long term, says Sudip Bandopadhyay

      Sudip Bandopadhyay, Market Expert recommends buying Sun Pharma with a view of more than a year.

    • Jubilant Life may hit Rs 578, see upside in Glenmark: Bodke

      Ajay Bodke of Prabhudas Lilladher is of the view that Jubilant Life Sciences may test Rs 578 and expects upside in Glenmark Pharma.

    • Pharma looks attractive for long term, says Dipan Mehta

      Dipan Mehta, Member at BSE & NSE is of the view that pharmaceuticals still looks very attractive for long term.

    • Bullish Sun Pharma; see over 20% rise by Dec '16: JP Morgan

      While JP Morgan warns of volatile quarterly results owing to one-time charges, it says the potential upside from the Ranbaxy deal in the medium-term (synergies from FY17 onwards) does strengthen the case for buying the stock at current levels.

    • Stick to frontline pharma, barring Sun Pharma: Jai Bala

      Jai Bala of 1857 Advisors recommends sticking to frontline pharma names barring Sun Pharmaceutical Industries.

    • Pick Lupin, Sun Pharma: Sudip Bandopadhyay

      Sudip Bandopadhyay of Destimoney Securities is of the view that one can pick Lupin abd Sun Pharma.

    • Opportunity to enter Sun Pharma, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that there is opportunity in Sun Pharma.

    • Buy pharma stocks: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying pharma stocks for investments including Sun Pharma.

    • Buy Wipro, Infosys: Siddarth Bhamre

      Siddarth Bhamre of Angel Broking recomennds buying Wipro and Infosys.

    • Lupin may test Rs 2600-2700: Prakash Diwan

      Prakash Diwan of prakashdiwan.in is of the view that Lupin may test Rs 2600-2700.

    • Positive on Sun Pharma, Strides Arcolab: Deepak Shenoy

      Deepak Shenoy of capitalmind.in has a positive stance on Sun Pharmaceutical Industries and Strides Arcolab.

    • Prefer Sun Pharma, LIC Housing, Infosys: Mayuresh Joshi

      Mayuresh Joshi of Angel Broking is of the view that one may prefer Sun Pharmaceutical, Infosys and LIC Housing Finance.

    • Buy Sun Pharma, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com advises buying Sun Pharmaceutical Industries.

    • Strides Arcolab top pick, says Gautam Trivedi

      According to Gautam Trivedi, MD & CEO of Religare Capital Markets, Strides Arcolab is a top pick in the midcap pharma space.

    • Look at Dr Reddy's Lab, Sun Pharma: Prakash Diwan

      According to Prakash Diwan of prakashdiwan.in, one may look at Dr Reddy's Laboratories, Glenmark Pharma and Sun Pharma from the pharmaceutical space.

    • Sun Pharma investment opportunity: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that Sun Pharma is an investment opportunity at the current level.

    • Stay with pharma, bullish on Sun Pharma: Sudip Bandopadhyay

      Sudip Bandopadhyay of Destimoney Securities is of the view that one may stay with pharma stocks and has a bullish stance on Sun Pharma.

    • Positive on Sun Pharma, says Ajay Bodke

      Ajay Bodke of Prabhudas Lilladher has a positive view on Sun Pharma.

    • Go long in Sun Pharmaceutical Industries: Sudarshan Sukhani

      According to Sudarshan Sukhani of s2analytics.com, one can go long in Sun Pharmaceutical Industries.

    • Stay with largecap pharma: Ajay Bagga

      Ajay Bagga, Market Expert is of the view that one may stay with largecap pharma.

    • Pick L&T, Dabur, Sun Pharma: Sharmila Joshi

      According to Sharmila Joshi of sharmilajoshi.com, one may prefer largecap stocks like Larsen and Toubro, Sun Pharma and Dabur India.

    • Keep Lupin, Sun Pharma in portfolio: Ambareesh Baliga

      Ambareesh Baliga, Independent Market Expert suggests to keep Lupin and Sun Pharmaceutical Industries in the portfolio.

    • Long on Sun Pharma, like midcap IT: Deepak Shenoy

      Deepak Shenoy of Capitalmind.in is of the view that one may go long in Sun Pharma and Strides Arcolab and likes midcap IT space including Sterlite Technologies.

    • Hold Sun Pharma, says Hemen Kapadia

      According to Hemen Kapadia of KRChoksey Securities, one may hold Sun Pharmaceutical industries.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347